Claims for Patent: 10,406,006

Summary for Patent: 10,406,006

Title:	Methods of providing optimized drug-eluting stent assemblies
Abstract:	Methods of providing a stent assembly that includes a stent jacket formed from an expansible mesh structure having apertures and that includes a fiber having a diameter of about 7 micrometers and about 40 micrometers, and an expansible stent operatively associated with the stent jacket. The method further comprises administering to the subject an active pharmaceutical ingredient (API) eluted from the stent assembly.
Inventor(s):	Bar; Eli (Moshav, IL), Holzer; Asher (Raanana, IL), Paz; Ofir (Rishon Lezion, IL)
Assignee:	INSPIREMD, LTD. (Tel Aviv, IL)
Application Number:	15/366,703
Patent Claims:	1. A method of providing a stent assembly which comprises: providing a stent configured to be positioned in the body lumen; and disposing a knitted stent jacket comprising an expansible mesh structure coaxially over a radial portion of the stent and along an entire length thereof, the mesh structure being formed from a single fiber and having a coverage area over the stent of about 10% to less than 20% relative to the total coverage area over the stent including a plurality of apertures therein, the apertures having approximate aperture diameters greater than 20 micrometers up to a minimum center dimension of 234 micrometers, wherein the stent assembly is configured to elute an amount of an active pharmaceutical agent that is present therein, and wherein the fiber has a diameter of approximately 7 micrometers to 40 micrometers. 2. The method of claim 1, which comprises eluting the active pharmaceutical agent from the stent. 3. The method of claim 1, which comprises eluting the active pharmaceutical agent from a coating disposed over a portion of the stent. 4. The method of claim 1, which comprises releasing the active pharmaceutical agent over time according to a predetermined treatment schedule. 5. The method of claim 4, wherein the treatment schedule is selected to cover a period of 8 hours to a plurality of months. 6. The method of claim 1, which comprises eluting the active pharmaceutical agent from the knitted stent jacket. 7. The method of claim 1, which comprises eluting the active pharmaceutical agent from a coating on the expansible mesh structure. 8. The method of claim 1, wherein disposing the knitted stent jacket coaxially over the stent further comprises sewing, adhering, gluing, folding, or suturing the knitted stent jacket to the stent. 9. The method of claim 8, wherein disposing the knitted stent jacket coaxially over the stent further comprises suturing the knitted stent jacket to the stent. 10. The method of claim 1, wherein the disposing the knitted stent jacket coaxially over the stent further comprises slidingly attaching a proximal portion of the knitted stent jacket to a proximal portion of the stent. 11. The method of claim 10, which further comprises slidingly attaching a distal portion of the stent jacket to a distal portion of the stent. 12. The method of claim 1, wherein the amount of active pharmaceutical agent eluted comprises a therapeutically effective amount to treat a disorder in a carotid or coronary artery, or a cerebral aneurism. 13. The method of claim 12, wherein the active pharmaceutical agent is eluted from any combination of the stent, a coating on the stent, the knitted stent jacket, or a coating on the knitted stent jacket. 14. The method of claim 1, which comprises forming the single fiber of the mesh structure from a polymer. 15. The method of claim 14, wherein the polymer comprises one or more of a poly lactic-co-polyglycolic ("PLGA"), polycaprolactone ("PCL"), polygluconate, polylactic acid-polyethylene oxide, poly(hydroxybutyrate), polyanhydride, poly-phosphoester, poly(amino acids), poly-L-lactide, poly-D-lactide, polyglycolide, or poly(alpha-hydroxy acid) co-polymer(s), polyethylene terephthalate, polytetrafluoroethylene, a polyvinyl alcohol, a polyamide, polypropylene, a polyurethane, or any combination thereof. 16. The method of claim 14, wherein the polymer is elastic, biocompatible, and hemocompatible. 17. The method of claim 1, wherein the expansible mesh structure is selected to comprise a retracted state and a deployed state, and further selected to define apertures having a minimum center dimension of 150 micrometers to 200 micrometers in the deployed state. 18. The method of claim 1, wherein the expansible mesh structure is selected to comprise a retracted state and a deployed state, and further selected to define apertures having a minimum center dimension of 150 micrometers to 180 micrometers in the deployed state. 19. The method of claim 1, wherein the active pharmaceutical agent is selected to comprise zolimus, zotarolimus, sirolimus, taxol/paclitaxel, or a combination thereof. 20. The method of claim 1, wherein the active pharmaceutical agent is selected to comprise an anti-proliferative agent, an antithrombotic agent, an anticoagulant, an antioxidant, a growth factor inhibitor, a collagen inhibitor, a liposome, a steroid or corticosteroid, a statin, endothelial cell seeds, a hydrogel containing endothelial cells, or a combination thereof. 21. The method of claim 20, wherein the anti-proliferative agent is present and comprises sirolimus, zolimus or zotarolimus, a taxane, tacrolimus, everolimus, vincritine, viblastine, a HMG-CoA reductase inhibitor, doxorubicin, colchicine, actinomycin D, mitomycin C, cycloporine, mycophenolic acid, triazolopyrimidine, or a combination thereof; wherein the antithrombotic agent is present and comprises heparin, a heparin-like dextran derivative, acid citrate dextrose, coumadin, warfarin, streptokinase, anistreplase, tissue plasminogen activator (tPA), urokinase, abciximab, or a combination thereof; wherein the growth factor inhibitor is present and comprises tranilast, angiopeptin, or a combination thereof; wherein the steroid or corticosteroid is present and comprises cortisone, prednisolone, or both; wherein the statin is present and comprises simvastatin, lovastatin, or a combination thereof; or any combination of the foregoing. 22. The method of claim 1, wherein the stent assembly is selected to comprise 1 microgram to 200 micrograms of the active pharmaceutical agent. 23. The method of claim 1, wherein the mesh of the knitted stent jacket is selected to comprise 1 microgram to 200 micrograms of the active pharmaceutical agent. 24. The method of claim 1, wherein the active pharmaceutical agent is selected to comprise sirolimus, zolimus, zotarolimus, or everolimus at a concentration of 10 .mu.g/mm.sup.2 to 80 .mu.g/mm.sup.2. 25. The method of claim 1, wherein the active pharmaceutical agent is selected to comprise sirolimus, zolimus, zotarolimus, or everolimus drug at a concentration of 80 .mu.g/mm.sup.2 to 140 .mu.g/mm.sup.2. 26. The method of claim 2, wherein the stent is selected to comprise a metal alloy coated with a biodegradable polymer, biostable polymer, bioresorbable polymer, or a combination thereof. 27. The method of claim 1, wherein the stent is selected to comprise a biodegradable polymer. 28. The method of claim 1, wherein the stent is selected to comprise a biodegradable metal alloy. 29. A method of providing a stent assembly which comprises: providing a stent configured to be positioned in the body lumen; coaxially disposing a knitted stent jacket comprising an expansible mesh structure over a circumference of the stent and along a length thereof, the mesh structure being formed from a single fiber and having a coverage area of about 9% to less than 16% relative to the coverage area of a plurality of apertures therein, the apertures having approximate aperture diameters greater than 20 micrometers up to a minimum center dimension of 234 micrometers; and providing at least one coating on an inner side or an outer side of the knitted stent jacket; wherein the stent assembly elutes an amount of an active pharmaceutical agent that is present therein, and wherein the fiber has a diameter of approximately 7 micrometers to 40 micrometers.

Details for Patent 10,406,006

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2026-11-22
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2026-11-22